Control patients without improvement will cross over to receive remestemcel-L at 3 months and may be retreated at 6 months. All patients will be followed for two years post initial treatment.
Yes Wilbs, the trials involving Rem-l for Chrons and Ulcerative Colitis have crossover of controls.
Given that there is pathological similarities with inflammation in the gastro intestinal tract and other organs, I am of the view that the efficacy signal stated by P Krause in aGvHD and early Amy Lightner updates at Ecco of early Rem-l success, plus the new complete healing results I recently posted for msc's , will culminate in IBD being partnered and rather quickly.
All these early trials with a primary endpoint of safety and feasibility are CURING the patients.
Waiting sucks
Viva la Revolucion
El Reg
2023 Next Steps, page-157
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |